These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 10146987)

  • 1. Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.
    Whittington R; Barradell LB; Benfield P
    Pharmacoeconomics; 1993 Jan; 3(1):45-82. PubMed ID: 10146987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.
    Dunn CJ; Wagstaff AJ
    Drugs Aging; 1995 Aug; 7(2):131-56. PubMed ID: 7579784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dosage epoetin in maintenance haemodialysis: costs and quality-of-life improvement.
    Harris DC
    Pharmacoeconomics; 1994 Jan; 5(1):18-28. PubMed ID: 10146863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the costs and benefits of recombinant human erythropoietin (epoetin) in the treatment of chronic renal failure in 5 European countries.
    Leese B; Hutton J; Maynard A
    Pharmacoeconomics; 1992 May; 1(5):346-56. PubMed ID: 10146999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.
    Dunn CJ; Markham A
    Drugs; 1996 Feb; 51(2):299-318. PubMed ID: 8808169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A decision analysis comparing three dosage regimens of subcutaneous epoetin in continuous ambulatory peritoneal dialysis.
    Piccoli A; Puggia RM; Fusaro M; Favaro E; Pillon L
    Pharmacoeconomics; 1995 May; 7(5):444-56. PubMed ID: 10155331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.
    Collins AJ
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii2-6. PubMed ID: 12819293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving therapeutic targets in renal anaemia: considering cost-efficacy.
    Deray G
    Curr Med Res Opin; 2004 Jul; 20(7):1095-101. PubMed ID: 15265254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost implications to Medicare of recombinant erythropoietin therapy for the anemia of end-stage renal disease.
    Powe NR; Griffiths RI; Bass EB
    J Am Soc Nephrol; 1993 Apr; 3(10):1660-71. PubMed ID: 8318682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits and costs of recombinant human erythropoietin for end-stage renal failure: a review. Benefits and costs of erythropoietin.
    McNamee P; van Doorslaer E; Segaar R
    Int J Technol Assess Health Care; 1993; 9(4):490-504. PubMed ID: 8288425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cost minimisation analysis for darbepoetin alpha vs. epoetin alpha in chronic kidney disease patients on haemodialysis].
    Cuesta Grueso C; Poveda Andrés JL; Garcia Pellicer J; Romá Sánchez E
    Farm Hosp; 2010; 34(2):68-75. PubMed ID: 20206567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
    Moran LJ; Carey P; Johnson CA
    Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal disease.
    Brophy DF; Ripley EB; Holdford DA
    Expert Opin Pharmacother; 2003 Sep; 4(9):1461-9. PubMed ID: 12943475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential cost savings of erythropoietin administration in end-stage renal disease.
    Hynes DM; Stroupe KT; Greer JW; Reda DJ; Frankenfield DL; Kaufman JS; Henderson WG; Owen WF; Rocco MV; Wish JB; Kang J; Feussner JR
    Am J Med; 2002 Feb; 112(3):169-75. PubMed ID: 11893342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probabilistic cost-minimisation analysis of darbepoetin alpha versus epoetin alpha in treating anaemia secondary to chronic renal failure. Assessment in Spanish clinical practice.
    Sanz-Granda A
    Farm Hosp; 2009; 33(4):208-16. PubMed ID: 19712609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer.
    Cheer SM; Wagstaff AJ
    Drugs; 2004; 64(3):323-46. PubMed ID: 14871172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human erythropoietin in end-stage renal disease.
    Bihl G
    S Afr Med J; 2002 Aug; 92(8):565. PubMed ID: 12244602
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacologic adjuvants to epoetin in the treatment of anemia in patients on hemodialysis.
    Berns JS; Mosenkis A
    Hemodial Int; 2005 Jan; 9(1):7-22. PubMed ID: 16191049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfusion therapy: associated risks and alternative approaches.
    Picard VT; Sayers MH; Spinowitz BS; Richner RE
    ANNA J; 1990 Dec; 17(6):457-64. PubMed ID: 2256728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.